Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)

INTRODUCTION: Clozapine and olanzapine are some of the most effective antipsychotics, but both are associated with weight gain and relevant metabolic disturbances, including pre-diabetes and diabetes. Non-pharmacological/behavioural interventions have had limited effects counteracting these adverse...

Descripción completa

Detalles Bibliográficos
Autores principales: Sass, Marie Reeberg, Danielsen, Andreas Aalkjær, Köhler-Forsberg, Ole, Storgaard, Heidi, Knop, Filip K, Nielsen, Mette Ødegaard, Sjödin, Anders Mikael, Mors, Ole, Correll, Christoph U, Ekstrøm, Claus, Vinberg, Maj, Nielsen, Jimmi, Vilsbøll, Tina, Fink-Jensen, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Mental Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890830/
https://www.ncbi.nlm.nih.gov/pubmed/36720576
http://dx.doi.org/10.1136/bmjopen-2022-068652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890830/
https://www.ncbi.nlm.nih.gov/pubmed/36720576
http://dx.doi.org/10.1136/bmjopen-2022-068652

Ejemplares similares